Dr. Andrew Magyar is Co-Founder and Chief Technology Officer of Capra Biosciences, where he leads development of a modular, continuous biomanufacturing platform designed to enable cost-competitive domestic production of pharmaceutical ingredients and specialty chemicals. Capra’s technology addresses critical supply chain vulnerabilities through its innovative, flexible, scalable, and geographically distributed manufacturing platform.
Dr. Magyar
has led the design, development and construction of Capra’s Sterling, Virginia
manufacturing facility and has driven the expansion of Capra's product pipeline
to more than ten molecules, including essential medicines such as acetaminophen
and aspirin. He is the principal investigator of Capra's HHS/IBMSC-funded
CoMPASS project focused on building an AI-enabled pipeline to rapidly develop
and scale the manufacture of biologically-derived small molecule APIs.
Previously, Dr. Magyar was a Principal Scientist at Draper, where he led over
$30 million in programs spanning biotechnology, advanced instrumentation and
integrated systems. Dr. Magyar received his Ph.D. in Materials Science from
Massachusetts Institute of Technology and completed his postdoctoral research
at Harvard University. He currently serves on the Safety and Security Committee
for BioMADE, a Manufacturing Innovation Institute sponsored by the US
Government.